Pfizer Inc
- All
- News
- Videos
-
US Health Advisers Back Pfizer, Merck Pneumonia Shots For Adults Over 50
A key panel of US health advisers voted in favor of lowering the age recommendation for vaccines made by Pfizer Inc and Merck & Co that protect against pneumococcal disease, clearing a path for wider use.
-
Pfizer's Updated Covid Shot Effective Against New Variant In Mice Study
Pfizer Inc said on Thursday its updated COVID-19 shot, which is being tested against emerging variants, showed neutralizing activity against the "Eris" subvariant in a study conducted on mice.
-
New Zealand Links 26-Year-Old Man's Death To Pfizer Covid Vaccine
New Zealand authorities on Monday said they had linked a 26-year-old man's death to Pfizer Inc's COVID-19 vaccine after the person suffered myocarditis, a rare inflammation of the heart muscle, after taking his first dose.
-
New Zealand Approves Pfizer Covid Vaccine For Children Aged 5-11
New Zealand's health regulator Medsafe has granted provisional approval for the Pfizer Inc COVID-19 vaccine for children aged 5 to 11 years old, the health ministry said in a statement.
-
Pfizer Covid Pill Nearly 90% Effective, Works On Omicron, Shows Lab Data
Pfizer Inc on Tuesday said final analysis of its antiviral COVID-19 pill still showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the fast
-
Pfizer's Covid Vaccine Trial Data Shows Long-Term Efficacy In Adolescents
Pfizer Inc said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.
-
Pfizer Says Its Antiviral Pill Cuts Risk Of Severe Covid By 89%
A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease.
-
What To Know About COVID-19 Vaccine For US Children
The US Food and Drug Administration is considering authorizing a COVID-19 vaccine for children aged 5 to 11. The vaccine from Pfizer Inc and BioNTech SE has been available in the United States to kids aged 12 to 15 since May.
-
US To Weigh Authorisation Of Pfizer Covid Vaccine For Children Aged 5-11
An expert panel will weigh authorization of Pfizer Inc and BioNTech's COVID-19 vaccine for children aged 5 to 11 on Tuesday as it prepares to vote on a recommendation for the US Food and Drug Administration.
-
Pfizer Submits Initial Data For Covid Vaccine Booster Authorization
Pfizer Inc and its German partner BioNTech SE have submitted to U.S. regulators the initial data from an early-stage trial toward seeking authorization of a booster dose of their COVID-19 vaccine, the drugmakers said on Monday.
-
US Health Advisers Back Pfizer, Merck Pneumonia Shots For Adults Over 50
A key panel of US health advisers voted in favor of lowering the age recommendation for vaccines made by Pfizer Inc and Merck & Co that protect against pneumococcal disease, clearing a path for wider use.
-
Pfizer's Updated Covid Shot Effective Against New Variant In Mice Study
Pfizer Inc said on Thursday its updated COVID-19 shot, which is being tested against emerging variants, showed neutralizing activity against the "Eris" subvariant in a study conducted on mice.
-
New Zealand Links 26-Year-Old Man's Death To Pfizer Covid Vaccine
New Zealand authorities on Monday said they had linked a 26-year-old man's death to Pfizer Inc's COVID-19 vaccine after the person suffered myocarditis, a rare inflammation of the heart muscle, after taking his first dose.
-
New Zealand Approves Pfizer Covid Vaccine For Children Aged 5-11
New Zealand's health regulator Medsafe has granted provisional approval for the Pfizer Inc COVID-19 vaccine for children aged 5 to 11 years old, the health ministry said in a statement.
-
Pfizer Covid Pill Nearly 90% Effective, Works On Omicron, Shows Lab Data
Pfizer Inc on Tuesday said final analysis of its antiviral COVID-19 pill still showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the fast
-
Pfizer's Covid Vaccine Trial Data Shows Long-Term Efficacy In Adolescents
Pfizer Inc said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.
-
Pfizer Says Its Antiviral Pill Cuts Risk Of Severe Covid By 89%
A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease.
-
What To Know About COVID-19 Vaccine For US Children
The US Food and Drug Administration is considering authorizing a COVID-19 vaccine for children aged 5 to 11. The vaccine from Pfizer Inc and BioNTech SE has been available in the United States to kids aged 12 to 15 since May.
-
US To Weigh Authorisation Of Pfizer Covid Vaccine For Children Aged 5-11
An expert panel will weigh authorization of Pfizer Inc and BioNTech's COVID-19 vaccine for children aged 5 to 11 on Tuesday as it prepares to vote on a recommendation for the US Food and Drug Administration.
-
Pfizer Submits Initial Data For Covid Vaccine Booster Authorization
Pfizer Inc and its German partner BioNTech SE have submitted to U.S. regulators the initial data from an early-stage trial toward seeking authorization of a booster dose of their COVID-19 vaccine, the drugmakers said on Monday.
